Nuveen Asset Management LLC Reduces Stake in Alto Neuroscience, Inc. (NYSE:ANRO)

Nuveen Asset Management LLC reduced its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 30.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,953 shares of the company’s stock after selling 61,310 shares during the quarter. Nuveen Asset Management LLC owned about 0.52% of Alto Neuroscience worth $592,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ANRO. Rhumbline Advisers grew its holdings in shares of Alto Neuroscience by 24.4% during the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after purchasing an additional 5,008 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Alto Neuroscience by 15.0% during the 4th quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company’s stock valued at $221,000 after purchasing an additional 6,812 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Alto Neuroscience in the fourth quarter worth approximately $74,000. Wellington Management Group LLP grew its position in Alto Neuroscience by 27.2% during the fourth quarter. Wellington Management Group LLP now owns 77,146 shares of the company’s stock valued at $326,000 after buying an additional 16,510 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after purchasing an additional 3,139 shares during the period.

Analysts Set New Price Targets

A number of research firms recently issued reports on ANRO. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Alto Neuroscience in a research note on Thursday, May 15th. Finally, HC Wainwright initiated coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They issued a “buy” rating and a $10.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.40.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $2.37 on Friday. The firm has a market cap of $64.03 million, a PE ratio of -1.01 and a beta of 1.87. The firm has a fifty day moving average of $2.37 and a 200 day moving average of $3.29. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience, Inc. has a one year low of $1.60 and a one year high of $17.55.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.06. As a group, research analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.